Healthcare / Pharmaceutical RetailersShenzhen
$14.55
-0.11 (-0.75%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 17%
FCF escenarios
weak_data · normalized FCF $315.8M · quality 27.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.9B
P/E
58.2x
↑EV/EBITDA
10.9x
↓ROE
5.4%
↑Gross Margin
26.2%
↓Debt/Equity
1.44
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.7%
FCF CAGR
+155.1%
FCF margin
6.1%
FCF / Net income
5.52x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.33B · net income $114.2M · FCF $630.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10.33B | $10.33B | $9.57B | $9.19B | $7.82B |
| Net Income | $114.2M | $114.2M | $-188.8M | $133.1M | $229.4M |
| EBITDA | $712.2M | $712.2M | $408.6M | $806.1M | $767.3M |
| EPS | 0.28 | 0.28 | -0.47 | 0.33 | 0.57 |
| Gross Margin | 26.2% | 26.2% | 25.4% | 28.3% | 28.6% |
| Operating Margin | 2.2% | 2.2% | 0.3% | 3.7% | 5.3% |
| Net Margin | 1.1% | 1.1% | -2.0% | 1.4% | 2.9% |
| Balance Sheet | |||||
| Debt/Equity | 1.44 | 1.44 | 1.95 | 1.69 | 1.33 |
| Current Ratio | 0.92 | 0.92 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $630.5M | $630.5M | $315.8M | $-38.6M | $38.0M |
| Returns | |||||
| ROE | 5.4% | 5.4% | -9.3% | 5.8% | 10.3% |
| Valuation | |||||
| P/E | 58.20 | 58.20 | — | 60.06 | 31.19 |
| EV/EBITDA | 10.90 | 10.90 | 17.30 | 12.98 | 10.76 |
| P/B | 2.79 | 2.79 | 2.20 | 3.49 | 3.21 |
| Growth & Yield | |||||
| Revenue Growth | 7.9% | 7.9% | 4.1% | 17.5% | — |
| EPS Growth | 159.6% | 159.6% | -242.4% | -42.1% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
66.4%
EPS terminal req.
$1.29
Spread vs growth
93.1%
5Y implied EPS CAGR
41.0%
EPS terminal req.
$1.56
Spread vs growth
118.5%
10Y implied EPS CAGR
24.6%
EPS terminal req.
$2.52
Spread vs growth
135.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+18.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.47 → 0.28
Residual
+18.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.